Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmonary vascular disease--overview.

E M Cordasco

    Angiology
    |October 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Recent advancements have improved the diagnosis of pulmonary vascular diseases. New treatments for recurrent thromboembolic disease significantly reduce patient morbidity and mortality.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Aortobronchial Fistula: Keys to Successful Management.

    Angiology·2016
    Same author

    Permanent respiratory impairment and upper airway symptoms despite clinical improvement in patients with reactive airways dysfunction syndrome.

    The Science of the total environment·2001
    Same author

    Environmental pulmonary edema: an update.

    Reviews on environmental health·1998
    Same author

    Noncardiac pulmonary edema, newer environmental aspects. An update.

    Angiology·1995
    Same author

    Concentric tracheal and subglottic stenosis. Management using the Nd-YAG laser for mucosal sparing followed by gentle dilatation.

    Chest·1993
    Same author

    Demographics of long-term ventilator-dependent patients outside the intensive care unit.

    Cleveland Clinic journal of medicine·1991
    Same journal

    Refining Phenotype-Based Interpretation of SGLT2 Inhibitors After AMI Without Heart Failure.

    Angiology·2026
    Same journal

    Response to: "Integrating Noninvasive Liver Indices into Risk Stratification of Myocardial Infarction With Non-Obstructive Coronary Arteries".

    Angiology·2026
    Same journal

    Response to: "Beyond Traditional Risk Markers: Is FIB-4 Sufficient in MINOCA?"

    Angiology·2026
    Same journal

    Letter: Further Considerations on the Clinical Use of the Scottish Inflammatory Prognostic Score in STEMI No-Reflow Prediction.

    Angiology·2026
    Same journal

    Contextualizing Remodeling Endpoints in Endovascular Treatment for Symptomatic SISMAD.

    Angiology·2026
    Same journal

    <i>Response to the Letter to the Editor</i>: "Effect of Invasive Hemodynamic Monitoring on the Outcomes of Cardiogenic Shock in Patients With Acute Myocardial Infarction".

    Angiology·2026
    See all related articles

    Area of Science:

    • Pulmonary vascular diseases
    • Cardiovascular medicine
    • Hematology

    Background:

    • Pulmonary vascular diseases encompass a range of conditions affecting lung vasculature.
    • Recurrent thromboembolic disease poses significant health risks.
    • Advances in medical science are crucial for improving patient outcomes.

    Purpose of the Study:

    • To highlight recent progress in diagnosing pulmonary vascular diseases.
    • To discuss novel therapeutic developments for recurrent thromboembolic disease.

    Main Methods:

    • Literature review of diagnostic techniques.
    • Analysis of treatment strategies and their impact on clinical outcomes.

    Main Results:

    • Significant improvements in diagnostic accuracy for pulmonary vascular diseases.

    Related Experiment Videos

  • Substantial reduction in morbidity and mortality rates associated with recurrent thromboembolic disease due to recent therapeutic advances.

    • Conclusions:

    • The past decade has seen notable progress in the diagnosis and treatment of pulmonary vascular diseases.
    • Current treatment strategies have led to a considerable decrease in adverse outcomes for patients with recurrent thromboembolic disease.